These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28484970)

  • 21. Discriminable stimuli produced by hallucinogens.
    Kuhn DM; White FJ; Appel JB
    Psychopharmacol Commun; 1976; 2(4):345-8. PubMed ID: 996285
    [No Abstract]   [Full Text] [Related]  

  • 22. MDMA-like behavioral effects of N-substituted piperazines in the mouse.
    Yarosh HL; Katz EB; Coop A; Fantegrossi WE
    Pharmacol Biochem Behav; 2007 Nov; 88(1):18-27. PubMed ID: 17651790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The psychopharmacology of hallucinogens.
    Abraham HD; Aldridge AM; Gogia P
    Neuropsychopharmacology; 1996 Apr; 14(4):285-98. PubMed ID: 8924196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The stimulus properties of LSD in C57BL/6 mice.
    Winter JC; Kieres AK; Zimmerman MD; Reissig CJ; Eckler JR; Ullrich T; Rice KC; Rabin RA; Richards JB
    Pharmacol Biochem Behav; 2005 Aug; 81(4):830-7. PubMed ID: 16005500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemistry and Structure-Activity Relationships of Psychedelics.
    Nichols DE
    Curr Top Behav Neurosci; 2018; 36():1-43. PubMed ID: 28401524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
    Solinas M; Goldberg SR
    Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
    Solinas M; Tanda G; Justinova Z; Wertheim CE; Yasar S; Piomelli D; Vadivel SK; Makriyannis A; Goldberg SR
    J Pharmacol Exp Ther; 2007 Apr; 321(1):370-80. PubMed ID: 17210800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 6-hydroxylated N,N-dimethyltryptamines and hallucinogenic potency.
    Uyeno ET
    Proc West Pharmacol Soc; 1969; 12():118-23. PubMed ID: 4980529
    [No Abstract]   [Full Text] [Related]  

  • 29. Classification of drugs according to their discriminable effects in rats.
    Barry H
    Fed Proc; 1974 Jul; 33(7):1814-24. PubMed ID: 4834184
    [No Abstract]   [Full Text] [Related]  

  • 30. Stimulus effects of three sulfur-containing psychoactive agents.
    Khorana N; Pullagurla MR; Dukat M; Young R; Glennon RA
    Pharmacol Biochem Behav; 2004 Aug; 78(4):821-6. PubMed ID: 15301941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of rigid analogues to probe hallucinogen receptors.
    Nichols DE; Weintraub HJ; Pfister WR; Yim GK
    NIDA Res Monogr; 1978; (22):70-83. PubMed ID: 101889
    [No Abstract]   [Full Text] [Related]  

  • 32. Serotonin and hallucinogens.
    Aghajanian GK; Marek GJ
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):16S-23S. PubMed ID: 10432484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psilocybin-induced stimulus control in the rat.
    Winter JC; Rice KC; Amorosi DJ; Rabin RA
    Pharmacol Biochem Behav; 2007 Oct; 87(4):472-80. PubMed ID: 17688928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early preclinical studies of discriminable sedative and hallucinogenic drug effects.
    Barry H; Appel JB
    Psychopharmacology (Berl); 2009 Apr; 203(2):193-201. PubMed ID: 18712362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hallucinogens as discriminative stimuli.
    Winter JC
    Fed Proc; 1974 Jul; 33(7):1825-32. PubMed ID: 4209212
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.
    Neelkantan N; Mikhaylova A; Stewart AM; Arnold R; Gjeloshi V; Kondaveeti D; Poudel MK; Kalueff AV
    ACS Chem Neurosci; 2013 Aug; 4(8):1137-50. PubMed ID: 23883191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvinorin B derivatives, EOM-Sal B and MOM-Sal B, produce stimulus generalization in male Sprague-Dawley rats trained to discriminate salvinorin A.
    Peet MM; Baker LE
    Behav Pharmacol; 2011 Sep; 22(5-6):450-7. PubMed ID: 21814135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
    Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
    J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.